• By ICR Secretariat
  • Posted Thursday, January 19, 2023

'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines

https://www.fiercepharma.com/fierce-biotech-homepage/top-line-fdas-stance-cancer-drug-approval-plus-weeks-headlines

The FDA is making some changes in the accelerated approval process. In this episode, we’ll discuss the recent changes with the FDA’s regulation of cancer drugs and how these shifts will impact the biopharma industry.